Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31331970 | 1.00 | HTR2A (0.58) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL7423539 | 0.88 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL31618095 | 0.88 | MTNR1A (0.56) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL8757942 | 0.84 | MTNR1A (0.42) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL12013659 | 0.83 | HTR2A (0.65) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL27837375 | 0.81 | HTR2A (0.55) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL15747778 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1B | |
| SCHEMBL14724998 | 0.80 | HTR2A (0.60) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL3279789 | 0.79 | HTR2A (0.63) | HTR2AMTNR1AMTNR1BHTR2CHTR2B | |
| SCHEMBL12550704 | 0.79 | HTR2A (0.63) | HTR2AMTNR1AMTNR1BHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333371-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-10-30 | — | — | US | disclosed |
| EP-4532462-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023230649-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-12-07 | — | — | WO | disclosed |
| US-9604911-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2017-03-28 | — | — | US | disclosed |
| US-20160368859-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2016-12-22 | — | — | US | disclosed |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-6583319-B1 | Treating or preventing melatoninergic disorders | LES LABORATOIRES SERVIER (FR) | 2003-06-24 | — | — | US | disclosed |
| EP-0994102-B1 | Cyclic derivatives with a cycloalkylenic chain, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-03-19 | — | — | EP | disclosed |
| EP-0994102-A1 | Cyclic derivatives with a cycloalkylenic chain, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368859-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | HTR2A 45/4885MTNR1A 232/4885MTNR1B 177/4885 |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN1, KCNN3, KCNN2 | HTR2A 2344/4885MTNR1A 357/4885MTNR1B 345/4885 |
| US-20250333371-A1 | COMPOUNDS | SDHA, PYGB, SLC18A2 | HTR2A 225/4885MTNR1A 1247/4885MTNR1B 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.